Jaguar Animal Health Inc (NASDAQ:JAGX) along with Napo Pharmaceuticals, Inc. posted that Dr. Pravin Chaturvedi has been elected as Chair of Scientific Advisory Board, subsequent to the projected completion of the merger of the two firms.
Dr. Chaturvedi has been chairing Napo Scientific Advisory Board since last couple of months. He is accountable for offering supervision on tactics, oversight and plans related to the commercialization and development of the drug pipelines, constituting, but not restricted to, SB-300 and Mytesi®.
From 2006 to 2013, Dr. Chaturvedi was CSO of the Napo and since then has remained a scientific adviser for the company. His notable record of accomplishments constitutes participating in, and directing development plans for 7 drugs, counting Mytesi®, which is authorized by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in subjects with HIV/AIDS and on antiretroviral therapy.
For this specific indication, Dr. Chaturvedi supervised the key opinion leader plans that led to the application of adaptive clinical study format for the Mytesi® study and its nod by the U.S. FDA. As confirmed earlier, Jaguar and Napo had successfully finalized a definitive merger contract.
The two firms are in the course of assessing follow-on indications for Mytesi® under the predicted combination of the product pipelines. Dr. Chaturvedi is chairing Mytesi® study for likely follow-on indications, which constitute irritable bowel syndrome, chemotherapy-related diarrhea, for which POC statistics are already present.
Napo recently planned a Scientific Advisory Board expo with professional gastroenterologists, who presented views on trial subjects and format in IBD and IBS. Douglas Drossman, MD mentioned that the safety profile of crofelemer constitutes a benefit that separates it from other gastrointestinal offerings.
In the last trading session, the stock price of Jaguar declined more than 4% to close the day at $0.660. After the recent decline, the market cap of firms stands around $9.27 million.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.financialstrend.com